CAMARILLO, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--AskGene, a biotechnology company developing next-generation cytokine therapeutics, and novel bi-specific antibodies to treat cancer and other diseases, and ATUM, a California-based bioengineering company, today announced the successful Investigational New Drug (IND) filing in China for AskGene’s new antibody drug. The antibody was produced using the Leap-In Transposase® technology pioneered by ATUM and represents the tenth successful IND clearance globally using this platform.